L-N-tert-butoxycarbonylcyclohexylalanine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-N-tert-butoxycarbonylcyclohexylalanine
• 英文别名: (2S)-2-[[1-[(2-methylpropan-2-yl)oxycarbonyl]cyclohexyl]amino]propanoic acid
• 化学式: C₁₄H₂₅NO₄
• 分子量: 271.357
• InChiKey: ZRMIZIBECLRTSY-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Bradykin B1receptor antagonists
  申请人：PHARMACOPEIA, INC.

  公开号：US20030229092A1

  公开（公告）日：2003-12-11

  Bradykinin B 1 -receptor antagonists of formula 1 are disclosed. The compounds are useful for treating diseases associated with inappropriate bradykinin receptor activity, such as diabetic vasculopathy, inflammation, pain, hyperalgesia, asthma, rhinitis, septic shock, atherosclerosis and multiple sclerosis. Pyrimidines, triazines, and anilines in which Q is imidazolyl or pyrrolyl are particularly preferred.

  Bradykinin B1受体拮抗剂的化学式1已被披露。这些化合物可用于治疗与不当的激肽酶受体活性相关的疾病，如糖尿病血管病变、炎症、疼痛、过敏症、哮喘、鼻炎、脓毒性休克、动脉粥样硬化和多发性硬化等。特别偏爱嘧啶、三嗪和苯胺类化合物，其中Q为咪唑基或吡咯基。
• Pryanone compounds useful as reversible inhibitors of cysteine proteases
  申请人：Bekkali Younes

  公开号：US20050026904A1

  公开（公告）日：2005-02-03

  Disclosed are cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (Ia) and (Ib) where R 2 , R 3 , R 4 , R 6 , R 8 and Y are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.

  本发明涉及公开的具有化学式（Ia）和（Ib）的cathepsin S，K，F，L和B可逆抑制化合物，其中R2，R3，R4，R6，R8和Y在此定义。该化合物可用于治疗自身免疫和其他疾病。还公开了制备这种新化合物的方法。
• Compounds useful as reversible inhibitors of cysteine proteases
  申请人：Boehringer Ingelheim Pharmaceuticals, Inc.

  公开号：US20040053921A1

  公开（公告）日：2004-03-18

  Disclosed are cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (Ia) and (Ib) where R 2 , R 3 , R 4 , R 6 , R 8 and Y are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds. 1

  本发明揭示了公式(Ia)和(Ib)中的cathepsin S、K、F、L和B可逆抑制化合物，其中R2、R3、R4、R6、R8和Y在此定义。这些化合物可用于治疗自身免疫和其他疾病。还揭示了制备这种新化合物的方法。
• N-acylamino acid derivatives and their use
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP0309766A2

  公开（公告）日：1989-04-05

  An N-acylamino acid derivative of the formula: wherein each of R¹, R², R⁴ and R⁶ is hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl or a monocyclic or bicyclic heterocyclic group containing from 1 to 4 hetero atoms; each of R³ and R⁵ is hydrogen or lower alkyl; A is -CH(OH)-(CH₂)qR⁷ wherein R⁷ is hydrogen, lower alkyl, cycloalkyl, cyloalkylalkyl, aryl, aralkyl, a monocyclic or bicyclic heterocyclic group containing from 1 to 4 hetero atoms or -E-R¹⁰ wherein E is -S(O)i- wherein i is 0, 1 or 2, oxygen, -NR¹¹- wherein R¹¹ is hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl, or wherein each of R¹² and R¹³ is hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl, and R¹⁰ is hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl or a monocyclic or bicyclic heterocyclic group containing from 1 to 4 hetero atoms provided that when R¹⁰ is hydrogen, i is 0, and q is an integer of from 0 to 5; or -CH₂-CHR⁸-CO-R⁹ wherein R⁸ is hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl or a monocyclic or bicyclic heterocyclic group containig from 1 to 4 hetero atoms, and R⁹ is hydroxyl, -OX wherein X is alkyl, aryl, lower alkoxycarbonyloxyalkyl or 1-phthalidyl, or -N(Y¹)(Y²) wherein each of Y¹ and Y² is hydrogen, lower alkyl, aryl, aralkyl or cycloalkyl, or Y¹ and Y² form together with the adjacent nitrogen atom a 5- or 6-membered heterocyclic group which may contain a further hetero atom; m is 0, 1 or 2; and n is an integer of from 1 to 5, provided that when R¹ is hydrogen, m is 0; or a salt thereof, which is useful as hypotensive drugs.

  一种 N-酰基氨基酸衍生物，其式如下 其中 R¹、R²、R⁴ 和 R⁶ 各为氢、低级烷基、环烷基、环烷基烷基、芳基、芳烷基或含有 1 至 4 个杂原子的单环或双环杂环基团；R³ 和 R⁵ 各为氢或低级烷基；A 是 -CH(OH)-(CH₂)qR⁷，其中 R⁷ 是氢、低级烷基、环烷基、环烷基烷基、芳基、芳烷基、含有 1 至 4 个杂原子的单环或双环杂环基团或 -E-R¹⁰ ，其中 E 是 -S(O)i- 其中 i 是 0、1或2、氧、-NR¹¹- 其中R¹¹是氢、低级烷基、环烷基、环烷基烷基、芳基或芳烷基，或 其中 R¹² 和 R¹³ 均为氢、低级烷基、环烷基、环烷基烷基、芳基或芳烷基，且 R¹⁰ 为氢、低级烷基、环烷基、环烷基烷基、芳基、芳烷基或含有 1 至 4 个杂质原子的单环或双环杂环基团，但当 R¹⁰ 为氢时，i 为 0，q 为 0 至 5 的整数；或-CH₂-CHR⁸-CO-R⁹，其中 R⁸ 是氢、低级烷基、环烷基、环烷基烷基、芳基、芳烷基或含有 1 至 4 个杂原子的单环或双环杂环基团，且 R𠞙 是羟基、-OX，其中 X 是烷基、芳基、或-N(Y¹)(Y²)，其中 Y¹ 和 Y² 分别为氢、低级烷基、芳基、芳烷基或环烷基，或 Y¹ 和 Y² 与邻近的氮原子一起形成 5 或 6 元杂环基团，该杂环基团可能含有另一个杂原子；m为0、1或2；n为1至5的整数，但当R¹为氢时，m为0；或其盐，可用作降血压药物。
• BRADYKININ B1 RECEPTOR ANTAGONISTS
  申请人：PHARMACOPEIA, INC.

  公开号：EP1196411A1

  公开（公告）日：2002-04-17